Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Ovarian Neoplasms 1Neoplasm Metastasis 1Male Urogenital Diseases 1Genital Diseases, Male 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 51Specimen Handling 42enzalutamide 35Androgen Antagonists 34Radiosurgery 32Radiotherapy 31Prednisone 26darolutamide 24Abiraterone Acetate 24Leuprolide 22Docetaxel 22apalutamide 20Pluvicto 19abiraterone 18Standard of Care 18Triptorelin Pamoate 17Radiation 17Biopsy 16relugolix 15acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 14Blood Specimen Collection 13gallium 68 PSMA-11 12pembrolizumab 11X-Rays 11Surveys and Questionnaires 11luprolide acetate gel depot 10Carboplatin 10Methods 9Interviews as Topic 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Prostatic Neoplasms × gedatolisib × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡